Axon Enterprise, Inc. (NASDAQ:AXON) Shares Sold by Artemis Investment Management LLP

Artemis Investment Management LLP reduced its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 13.2% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 93,414 shares of the biotechnology company's stock after selling 14,249 shares during the period. Artemis Investment Management LLP owned about 0.12% of Axon Enterprise worth $29,216,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in AXON. Norges Bank bought a new position in shares of Axon Enterprise during the 4th quarter valued at approximately $195,406,000. Sands Capital Management LLC increased its stake in shares of Axon Enterprise by 31.1% in the third quarter. Sands Capital Management LLC now owns 2,612,305 shares of the biotechnology company's stock worth $519,823,000 after purchasing an additional 619,179 shares in the last quarter. Polar Capital Holdings Plc raised its position in shares of Axon Enterprise by 292.0% during the 3rd quarter. Polar Capital Holdings Plc now owns 265,464 shares of the biotechnology company's stock valued at $52,825,000 after purchasing an additional 197,746 shares during the period. International Assets Investment Management LLC purchased a new position in shares of Axon Enterprise during the 4th quarter valued at $39,907,000. Finally, Goldman Sachs Group Inc. boosted its holdings in Axon Enterprise by 110.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 276,011 shares of the biotechnology company's stock worth $71,302,000 after buying an additional 144,568 shares during the period. 79.08% of the stock is currently owned by institutional investors.

Axon Enterprise Price Performance

Shares of Axon Enterprise stock traded down $4.11 during trading hours on Friday, reaching $294.24. The company's stock had a trading volume of 1,083,268 shares, compared to its average volume of 497,012. The firm has a 50 day moving average price of $295.25 and a 200-day moving average price of $284.70. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.91 and a quick ratio of 2.55. The stock has a market cap of $22.21 billion, a P/E ratio of 86.04 and a beta of 0.91. Axon Enterprise, Inc. has a one year low of $175.37 and a one year high of $329.87.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its quarterly earnings data on Friday, May 10th. The biotechnology company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.20. The company had revenue of $460.74 million for the quarter, compared to analysts' expectations of $441.57 million. Axon Enterprise had a return on equity of 11.71% and a net margin of 15.60%. The firm's revenue for the quarter was up 34.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.51 earnings per share. On average, analysts predict that Axon Enterprise, Inc. will post 2.35 EPS for the current year.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, Director Julie A. Cullivan sold 478 shares of Axon Enterprise stock in a transaction on Tuesday, May 28th. The shares were sold at an average price of $286.04, for a total transaction of $136,727.12. Following the completion of the transaction, the director now directly owns 5,546 shares of the company's stock, valued at $1,586,377.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, Director Jeri Williams sold 308 shares of the company's stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $310.07, for a total transaction of $95,501.56. Following the transaction, the director now owns 1,607 shares of the company's stock, valued at $498,282.49. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Julie A. Cullivan sold 478 shares of the stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $286.04, for a total value of $136,727.12. Following the completion of the sale, the director now owns 5,546 shares in the company, valued at $1,586,377.84. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 89,447 shares of company stock worth $27,684,677. Company insiders own 6.10% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have commented on AXON. Craig Hallum raised their price target on Axon Enterprise from $325.00 to $370.00 and gave the company a "buy" rating in a report on Tuesday, May 7th. StockNews.com cut Axon Enterprise from a "buy" rating to a "hold" rating in a report on Thursday, March 14th. Needham & Company LLC reaffirmed a "buy" rating and set a $400.00 price objective on shares of Axon Enterprise in a report on Tuesday, May 7th. JPMorgan Chase & Co. lifted their price objective on shares of Axon Enterprise from $330.00 to $365.00 and gave the company an "overweight" rating in a research report on Thursday, April 11th. Finally, Argus initiated coverage on shares of Axon Enterprise in a research report on Wednesday, March 13th. They set a "buy" rating and a $380.00 target price for the company. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $335.27.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.